Pharmacological profile and clinical study results of darinaparsin (DARVIAS injection 135 mg), an organic arsenic product, for relapsed or refractory peripheral t-cell lymphoma (PubMed, Nihon Yakurigaku Zasshi) - Sep 8, 2023 - "launched this drug in August 2022. Darinaparsin is expected to contribute to the clinical practice of PTCL as a new treatment option for this disease."
Journal • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia
|
|
Fumiko Nagahama; Kozo Yao; Yusuke Sonehara
|